ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?
A human apolipoprotein A1 (ApoA1) product, which is the key constituent of high-density lipoprotein (HDL) cholesterol and removes excess lipid from atherosclerotic plaques, did not bring about a significant reduction in the primary endpoint of cardiovascular death, myocardial infarction (MI), or stroke in patients with MI and additional risk factors…
Read More
0
